We have identified a novel mechanism of cross-talk between cell signaling and metabolic pathways, whereby the signaling kinase p21-activated kinase 1 (Pak1) binds to, phosphorylates and enhances the enzymatic activity of phosphoglucomutase 1 (PGM), an important regulatory enzyme in cellular glucose utilization and energy homeostasis. Pak1 and PGM were colocalized in model cell systems and showed functional interactions in a physiological setting. Strong direct interaction of PGM with Pak1 but not Pak2, Pak3, or Pak4 was observed. PGM binding was within 75-149 amino acids (aa) of Pak1, while Pak1 binding to PGM was in the N-terminal 96 aa. Pak1-mediated phosphorylation of PGM selectively on threonine 466 significantly increased PGM enzymatic activity and could be blocked by transfection with a dominantnegative Pak1 expression vector and by Pak1-specific small inhibitory RNA. Stable transfection of PGM into PGM-deficient K-562 leukemia cells further demonstrated the role of Pak1 in regulating PGM activity. The results presented here provide new evidence that the cell signaling kinase Pak1 is a novel regulator of glucose metabolism through its phosphorylation and regulation of PGM activity. These findings suggest a new mechanism whereby growth factor signaling may coordinately integrate metabolic regulation with established signaling functions of cell cycle regulation and cell growth.
Introduction
Tumor cells typically demonstrate altered metabolism and a disruption of regulation of glycolytic metabolism, respiration and a specific high glucose-utilizing metabolic phenotype as compared to nontransformed cells. In particular, glycolytic metabolism is increased, as is the activity of the pentose phosphate cycle (Warburg, 1956) . Concurrently, a reduction in oxidative phosphorylation and fatty metabolism have also been reported, which results in increased uptake of glucose, altered redox state in the cells and induction of cell survival pathways (Unwin et al., 2003) . Inside the cell, following the conversion of glucose to glucose-6-phosphate (G-6-P) (via hexokinase or phosphoglucomutase (PGM)), the major pathways of glucose metabolism include glycolysis and the pentose phosphate pathway. Although it has been recognized that metabolic fluxes between glycolysis and the pentose phosphate pathway are particularly relevant for balancing cellular requirements for energy and reducing equivalent homeostasis, a lacuna exists in our understanding of the manner in which the cell regulates the rates of these two basic metabolic pathways in response to various extracellular stimuli.
The biochemical pathways required to utilize glucose as a carbon and energy source are highly conserved from bacteria to humans. PGM (EC 2.7.5.1) is an evolutionarily conserved enzyme that regulates one of the most important metabolic carbohydrate trafficking points in prokaryotic and eukaryotic organisms, catalysing the bidirectional interconversion of glucose-1-phosphate (G-1-P) and G-6-P. In one direction, G-1-P produced from sucrose catabolism is converted to G-6-P, the first intermediate in glycolysis. In the other direction, conversion of G-6-P to G-1-P generates a substrate for synthesis of UDP-glucose, which is required for synthesis of a variety of cellular constituents, including cell wall polymers and glycoproteins. PGM has been used extensively as a genetic marker for isozyme polymorphism among humans (Putt et al., 1993) . PGM is known to be post-translationally modified by cytoplasmic glycosylation that does not seem to regulate its enzymatic activity but rather is implicated in the localization of the protein (Dey et al., 1994) . Glucose 1,6 bisphosphate (Glc-1, 6-P2), a powerful regulator of carbohydrate metabolism, has been demonstrated to be a potent activator of PGM (Boros et al., 2002) . PGM is also modified by phosphorylation on Ser108 as part of its catalytic mechanism. However, no functional significance, other than its role in the enzymatic process itself, has been assigned to Ser108 phosphorylation, and a specific regulatory phosphorylation site and kinase have not been identified for PGM so far. Despite the critical role of PGM in cellular carbon flux and energy homeostasis, little is known regarding its functional regulation.
p21-activated kinase 1 (Pak1) is activated by growth factor receptor tyrosine kinases via Rac or Cdc42 (Adam et al., 1998 Vadlamudi et al., 2000) , by nonreceptor tyrosine kinases and by lipids (BagheriYarmand et al., 2001) . The Pak1 enzyme is conserved functionally through evolution from yeast to mammals. Wide ranges of biological activities have been shown to result from Pak1 phosphorylation of downstream substrates, including cell cytoskeletal reorganization leading to increased motility, enhanced cell survival and cross-talk with signaling pathways that influence gene expression Bokoch, 2003) . Pak1 participates in the activation of NADPH oxidase by phosphorylation of serine residues on p47 phox that are required for assembly and activity of the enzyme (Knaus et al., 1995; Bokoch, 2003) . The active enzyme complex uses NADPH to produce reactive oxygen intermediates that function in cell signaling, host defense and cell redox balance. Recently, it has also been reported that Pak1 inhibits phosphoglycerate mutase (PGAM), an enzyme of the glycolytic pathway causing a transient switch from glycolysis to pentose phosphate pathway utilization and enhanced NADPH production in neutrophils (Shalom-Barak and Knaus, 2002; Bokoch, 2003) .
Since the flux of glucose in the cells through the glycolytic pathway is responsive to mitogens, we hypothesized that Pak1, a major regulatory kinase that coordinates divergent pathways in response to growth factor signaling, may influence the metabolic shift in cells by modulating the activities of essential enzymes of glucose metabolism. Here we investigate the regulation of PGM phosphorylation and enzymatic activity by Pak1.
Results

Phosphorylation of PGM by Pak1
To test our hypothesis that PGM is a phosphorylation substrate for Pak1, we first confirmed that there were several potential Pak1 phosphorylation consensus motifs (R/K XX S/T) within the PGM amino-acid sequence ( Figure 1a ). An in vitro kinase assay was then carried out using purified Pak1 enzyme and GST-PGM protein as substrate to test Pak1 kinase activity against PGM. As shown in Figure 1b , wild-type Pak1 readily phosphorylated GST-PGM, while recombinant kinase dead-Pak1 enzyme (K299R) was unable to phosphorylate GST-PGM. The calculated phosphorylation stoichiometry was B0.65 mol of phosphate/mol of PGM (see Materials and methods for calculations). In order to validate the phosphorylation of PGM in vivo, we transfected a T7-tagged PGM expression vector into MCF-7 cells and metabolically labeled the cells with 32 P-labeled ATP. Immunoprecipitation of T7-PGM followed by SDS-PAGE and autoradiography indicated that PGM exists in a phosphorylated form in vivo. Lipids and sphingomyelinase, signals that are known to activate Pak1 in MCF-7 cells, stimulated PGM phosphorylation ( Figure 1c, top panel) . Co-transfection of the autoinhibitory fragment of Pak1 (83-149 amino acids (aa)) that acts in a dominant negative manner resulted in decreased PGM phosphorylation in response to sphingomyelinase, indicating that Pak1 was responsible, at least in part, for the phosphorylation of PGM in vivo. Immunoprecipitation of Pak1 from the same lysates and subsequent kinase assay using myelin basic protein as substrate (Figure 1c , lower panel) confirmed that Pak1 was activated upon stimulation with lipids and sphingomyelinase. In this panel, the activity of Pak1 was reduced as expected when the autoinhibitory fragment of Pak1 was transfected.
To identify the site(s) of Pak1 phosphorylation in PGM, GST-tagged PGM deletion constructs were subjected to in vitro kinase assay using recombinant Pak1. The C-terminal protein fragments containing 418-574 aa (i.e., deletion constructs numbers 3 and 4) were efficiently phosphorylated, while deletion of this region (i.e., deletion constructs numbers 5-7) resulted in abrogation of phosphorylation (Figure 1d ). Surprisingly, the fragment containing 90-574 aa (deletion construct number 2) was not phosphorylated. This could be because partial deletion of very few amino acids could create an overhang that could mask the phosphorylation site and make it inaccessible for phosphorylation by Pak1. However, the other deletion constructs are smaller and could have a more open structure that leaves the phosphorylation site exposed. It could thus be concluded that the Pak1 phosphorylation site on PGM was located between 418 and 574 aa. In this C-terminal domain, three potential Ser or Thr Pak1 phosphorylation consensus sites are present. Site-directed mutagenesis of these potential Ser or Thr consensus phosphorylation sites to Ala in the full-length GSTtagged PGM protein followed by in vitro phosphorylation of the purified mutant GST fusion proteins by Pak1 resulted in abrogation of phosphorylation only in the T466A mutant, while S459A and S504A mutants were phosphorylated to the same extent as the wild-type protein (Figure 1e ). This suggested that Pak1 phosphorylates PGM on only one site and that this phosphorylation site was threonine (Thr) 466. The above results indicate that PGM is indeed a bonafide substrate for Pak1 in vivo, with a single phosphorylation site at Thr 466. The stretch of amino acids surrounding the Pak1 phosphorylation site in PGM shows a high degree of conservation both in terms of amino-acid sequence and structure across a wide range of evolutionarily divergent organisms ( Figure 1f ): thus, Pak1 phosphorylation of PGM may be an evolutionarily conserved regulatory mechanism.
Identification of PGM as a Pak1 interacting protein
Initial in vitro PGM and Pak1 protein-protein interaction was established by a GST-pulldown assay, where in vitro translated PGM co-precipitated with GST-Pak1 (Figure 2a , upper panels). Conversely, in vitro translated Pak1 also interacted with GST-PGM in the GSTpulldown assay (Figure 2a, lower panels) . To determine the specificity of Pak1 and PGM interaction, GST-PGM was used in GST-pulldown assay along with in vitro translated Pak1, Pak2, Pak3 and Pak4. The strongest PGM binding was observed with Pak1, although Pak3, which shares high sequence homology with Pak1, also weakly interacted with PGM ( Figure 2b ). Pak2 and Pak4, on the other hand, did not significantly interact with PGM ( Figure 2b ).
Next we examined in vivo protein-protein interaction of Pak1 and PGM using two approaches. A one-on-one yeast co-transformation assay using either pGBD-Pak1
(1-270 aa) or pGBD-Pak1 (271-570 aa) and pGAD-PGM (full length) showed that the N-terminal half of Pak1 interacted in vivo with PGM, enabling the yeast cells to grow in stringent (-A-H-L-T) conditions. A known Pak1 interacting protein, Rac1, was used as a positive control (Figure 3a ). This in vivo interaction was further substantiated using co-immunoprecipitation studies. Immunoprecipitation of Pak1 and Western blotting for PGM in MCF-7 cells showed that the endogenous proteins interact with one another in a physiological setting (Figure 3b ). This interaction was , and, after 24 h, the cells were serum starved for another 24 h, labeled with 32 P-orthophosphate overnight and then treated with the lipid, sphingosine (100 mM) or sphingomylinase (SPM, 1 U/ml medium) for 30 min to stimulate Pak1 activity. In vivo phosphorylation of T7-PGM was assessed by immunoprecipitating the cell lysates with T7 antibody. The immunoprecipitates were resolved on a SDS-PAGE gel, and transferred to membranes. After autoradiography, the membranes were blotted with T7 antibody. Pak1 was immunoprecipitated from the same lysates using Pak1-specific antibody and an in vitro kinase reaction was carried out with MBP as substrate (lower panel). (d) GSTtagged PGM deletion constructs were used as substrates for Pak1 in an in vitro kinase assay. (e) Three PGM mutant proteins with mutation of putative phosphorylation sites, PGS459A, PGMT466A and PGMS504A, were used as substrates in the Pak1 in vitro kinase assay. (f) Sequence alignment of the region of PGM near the Pak phosphorylation site dependent on serum factors, since immunoprecipitation in the absence of 10% serum did not pull down any PGM protein. Furthermore, co-transfected T7-PGM (red) and myc-Pak1 (green) were distinctly colocalized in the cell upon stimulation by epidermal growth factor (EGF, a mitogenic activator of Pak1), as evidenced by confocal scanning microscopy ( Figure 3c ). Curiously, the two proteins seemed to localize together more in the edges of the cells towards the cell membrane upon EGF treatment. Thus, PGM and Pak1 interact physically with each other in the cells, enabling Pak1 to phosphorylate PGM. 
Mapping of PGM and Pak1-binding sites
Functional consequence of Pak-mediated phosphorylation of PGM
In order to verify if Pak1-mediated PGM phosphorylation altered the biological activity of PGM, PGM activity was assayed using purified recombinant PGM protein with and without preincubation in a Pak1 in vitro kinase assay. Results indicate that the specific activity of PGM increased twofold above basal levels after it was phosphorylated in vitro by the Pak1 enzyme (Figure 5a ). The phosphorylation of PGM by Pak1 was verified by SDS-PAGE and autoradiography using 20% of the kinase reaction product. The phosphorylation by Pak1 did not change the kinetics of the PGM reaction but increased the rate of the reaction, since the saturation time for the reaction did not change. The Slabeled Pak1 was incubated with GST-PGM in the GST-pulldown assays. The interaction was analysed by SDS-PAGE followed by autoradiography (upper panels). Full-length PGM was translated in vitro and 35 S-PGM was subjected to GST-pulldown assay using GST-tagged Pak1. The precipitated proteins were analysed by SDS-PAGE and autoradiography (lower panels). In each figure, the upper panel indicates the 35 S-labeled proteins, while the lower two panels show Ponceau staining of the blots to visualize the GST proteins. (b) PGM binding to Pak isoforms in a GST-pulldown assay using GST-PGM and specific activity of PGM did not change from basal levels when PGM activity was assayed in the presence of recombinant kinase dead-Pak1 enzyme (K299R) (Figure 5b ). T466A-PGM mutant (which cannot be phosphorylated by Pak1) showed no changes in its specific activity as compared to the basal activity of PGM after in vitro phosphorylation by either recombinant Pak1 or kinase dead-Pak1 enzymes (Figure 5c ). A linear fit was obtained when average velocity ([NADH]/ time) versus time was plotted, which was used to calculate the average velocity of each reaction (Figure 5d ). The average velocity of PGM activity was approximately twofold higher with Pak1 phosphorylation. Likewise, treatment of MCF-7 cells with a physiological signal that activates Pak1 (EGF) and increases phosphorylation of PGM (data not shown) caused an increase in the activity of PGM in these cells (Figure 5e ). To demonstrate that the changes in Binding was analysed by GST-pulldown assay, followed by SDS-PAGE and autoradiography. Lower panel depicts Ponceau staining of the blot Figure 5 Functional consequence of Pak-mediated phosphorylation of PGM. (a) Recombinant GST-tagged PGM was phosphorylated in vitro using recombinant Pak1 enzyme and PGM activity was assayed before and after in vitro Pak1 phosphorylation. GST was used as a negative control. (b) Recombinant GST-tagged PGM was phosphorylated in vitro using either recombinant Pak1 or kinase dead-Pak1 (K299R) enzymes and PGM activity was assayed before and after in vitro Pak1 phosphorylation. GST was used as a negative control. (c) Recombinant GST-tagged PGMT466A was phosphorylated in vitro using either recombinant Pak1 or kinase dead-Pak1 (K299R) enzymes and PGM activity was assayed before and after in vitro Pak1 phosphorylation. GST was used as a negative control. (d) Average velocity calculations for reactions performed in (b, c). A plot of average velocity versus time was used for linear regression fit and the velocity of the reaction was calculated. m is the slope of the reaction and R 2 gives the regression line fit. (e) MCF-7 cells were transiently transfected with the pCDNA vector or with the T7-PGM T466A phosphorylation mutant vector. The cells were serum starved for 48 h and then stimulated with EGF for 10 min. Cell lysates were assayed for PGM activity and normalized to fold activity of the enzyme. Equal amounts of protein were used for the enzyme assay. Values are averages of at least three independent estimations and are expressed as fold activity7s.e.m.
PGM regulation by Pak1 signaling
A Gururaj et al EGF-stimulated Pak1 kinase activity were necessary for increased PGM activity, either pcDNA (vector control) or T7-tagged phosphorylation point mutant, PGMT466A was transfected into MCF-7 cells and the cells were stimulated using EGF for 10 min. The cell lysates were collected and assayed for PGM activity. Cells expressing the pcDNA plasmid alone showed an increase in PGM activity upon EGF stimulation, as seen in nontransfected MCF-7 cells. Overexpression of the mutant PGM that could not be phosphorylated by Pak1 led to the inhibition of signal-stimulated activation of PGM in vivo (Figure 5e ), indicating that phosphorylation of PGM by Pak1 enhances the activity of PGM in vivo.
In order to elucidate the modulation of PGM by Pak1 in vivo, we utilized two cell lines expressing differing amounts of Pak1 as model systems. MCF-7 cells express modest amounts of Pak1 while MDA-MB-435 express high amounts of Pak1 (Adam et al., 1998) . Endogenous PGM activity in these cell lines was correlated with Pak1 and PGM protein expression (Figure 6a ). An increase in PGM activity was correlated with higher Pak1 and PGM expression in the MDA-MB-435 cells. When Pak1-specific siRNA (Barnes et al., 2003) was transfected to downregulate Pak1 expression, PGM activity was reduced by 40% in MCF-7 cells and 30% in MDA-MB-435 cells (Figure 6b ). Since the experiment was carried out in the presence of 10% serum, the results indicate that, under physiological conditions, Pak1 is required for PGM activity. The basal activity of PGM in MCF-7 cells grown in 0% serum did not change in the presence of Pak1-siRNA (Figure 6c) . However, the EGF-stimulated increase in activity of PGM was abrogated with Pak1 knockdown. Thus, it can be concluded that Pak1 activity is important for activation of PGM through Pak1-dependent signaling pathways but not necessary for basal activity of the enzyme.
We next used previously characterized MCF-7 cells stably transfected with a tetracycline-inducible dominant-active Pak1 plasmid to test the potential role of Pak1 regulation of PGM in vivo. Doxycycline treatment of these cells for 24 h increased protein expression of the inducible dominant-active Pak1, with no change in PGM protein expression (Figure 6d ). However, Pak1 induction was correlated with a significant increase in PGM activity (Figure 6d ). In control experiments using the parental cell line, no induction of Pak1 protein, PGM protein, or PGM enzymatic activity was observed with doxycycline treatment (data not shown). These results indicate that Pak1 specifically regulates PGM activity in vivo.
The K562 leukemia cell line is spontaneously deficient in PGM (Tomkins et al., 1997) . These cells do not express PGM protein, as detected by Western blot, and show very little or no PGM activity (Figure 7a ). We stably transfected T7-tagged PGM into the K562 cells and the stable clones demonstrated PGM activity (Figure 7a) . Although both the parental K-562 cells and the PGM-wild-type transfected K562 cells showed activation of Pak1 upon stimulation with sphingosine (Figure 7b ), PGM activity was stimulated only in PGMtransfected K562 cells (Figure 7c ). The time course of stimulation indicated that Pak1 was activated prior to peak activation of PGM in these cells. To examine the influence of PGM expression on the growth characteristics of K-562 cells, we measured the proliferation rate of both vector-transfected and PGM-transfected cells. The K-562 cells with PGM1 overexpression Lysates of MCF-7 cells and MDA-MB-435 cells were assayed for PGM activity. PGM and Pak1 protein levels in these cells were determined by Western blot analysis using specific antibodies for the proteins. (b) Control siRNA and Pak1-specific siRNA (5) were transfected into MCF-7 and MDA-MB-435 cells and the cells were harvested after 48 h. Cell lysates were prepared and PGM activity in the cells was determined as described in Materials and methods. Cell lysates were also analysed for expression of Pak1 by SDS-PAGE, followed by Western blotting using Pak1-specific antibody. (c) MCF-7 cells were transfected with siRNA for Pak1 and control siRNA. After 24 h, the cells were serum starved and stimulated with EGF for 10 min. Cell lysates were then assayed for PGM activity. Equal amounts of protein were used for the enzyme assay. Values are averages of at least three independent estimations and are expressed as fold activity7s.e.m. (d) MCF-7 cells stably transfected with a tetracycline-inducible dominant-active Pak1 plasmid were used for induction of Pak1 expression by addition of doxycycline (1 mg/ml medium) for 24 h. Lysates were prepared with and without doxycycline and PGM activity in the cell lysates was analysed. Equal amounts of protein were used for the enzyme assay. Values are averages of at least three independent estimations and are expressed as fold activity7s.e.m. Cell lysates were also used for Western blot analysis of PGM and Pak1 protein expression using specific Pak1 and PGM antibodies (lower panel) demonstrated a twofold increased growth rate as compared with vector-transfected control cells (Figure 7d ). These results from K562 cells strongly support our hypothesis that Pak1 regulates the activity of PGM in vivo.
Putative phosphorylation-induced changes in PGM conformation
Examination of the three-dimensional crystal structure of rabbit PGM (Figure 8a) showed that Thr 466 is in a position fully accessible to the solvent and could thus be covalently modified by phosphorylation. Substitution of Glu for Thr 466 using SwissProt analysis software, in order to mimic the addition of a charged phosphate group, resulted in the dissolution of hydrogen bonding between beta sheets 12 and 13 (Figure 8b) , and a gain of intrachain hydrogen bonds in beta strand 13 (Figure 8c ). This potential structural alteration with the addition of a phosphate group could cause a shift in a beta strand and loop that lie over one end of the PGM active site and thus alter access to this region, potentially increasing the enzymatic activity. In addition, alteration of the intracellular localization of PGM by physiological signals that activate Pak1 may also influence enzymatic activity (data not shown). Thus, Pak1 may induce relocalization of PGM to areas of glycogen storage or energy utilization in addition to increasing PGM activity in the intact cell.
Discussion
It has been shown that, in transformed cells, there is increased breakdown of glycogen to G-1-P, which can then enter the glycolytic pathway through the activity of The three-dimensional rendering of the rabbit PGM crystal structure (PDB 3PMG, created using the SwissProt PDBViewer) was examined for localization of the Thr 466 Pak1 phosphorylation site (shown) in relation to the active site. Phosphorylation of Thr 466 may disrupt interstrand hydrogen bonding (b) and instead create intrastrand hydrogen bonding (c), resulting in a putative contraction of a beta strand and beta turn overlying the active site entrance and increasing access to the active site (arrow) Figure 7 Validation studies using K562/PGM stable clones. (a) Stable clones of PGM in K-562 leukemia cells were generated and expression of PGM and Pak1 in these cells was checked by Western blot analysis. PGM activity in the stable clones was assayed as described in the Materials and methods section. (b) K-562 cells and PGM-expressing-K-562 clone 3 were treated with sphingosine (100 mM) for 10 min, then assayed for Pak1 kinase activity after immunoprecipitation of Pak1 using MBP as substrate. (c) PGM activity in parental K-562 cells and PGM-expressing-K-562 clone 3 was assayed after stimulation with sphingosine at different time intervals. (d) K-562 and PGM-overexpressing clone 3 were plated at a density of 2 Â 10 4 cells and cells were counted after 4 days interval. Values are averages of three independent experiments and are expressed as average cell number7s.e.m.
PGM (Boros et al., 2002) . Recently, it was reported that, in neutrophils, Pak1 inhibits PGAM, an enzyme of the glycolytic pathway, resulting in a transient switch from glycolysis to metabolism through the pentose phosphate pathway (Shalom-Barak and Knaus, 2002) and an increased cellular supply of NADPH. Thus, it is attractive to speculate that Pak1 phosphorylation of PGM acts in concert with its action on other Pak1 substrates to cause changes required for a specific metabolic shift towards the utilization of the pentose phosphate pathway in tumor cells. A recent report of kinetic measurements of PGM activity indicates that PGM preferentially converts G-1-P to G-6-P even when the two substrates are present in equimolar concentration in the reaction and the equilibrium constant of the reaction where G-6-P is used as a substrate is unfavorable (Gao and Leary, 2004) . This gives further support to our hypothesis that Pak1-induced PGM activity would drive the PGM reaction towards formation of G-6-P and thus glycolysis and pentose phosphate pathways. However, since direct flux measurements using tracer techniques were not employed in our study, we are unable to conclude definitively on the direction of PGM activity in the current context. NADPH derived from the pentose phosphate pathway is used as a substrate or cofactor in diverse regulatory pathways in the cell. Also, reactive oxygen species produced as a byproduct of NADPH oxidase activity (which is also upregulated by Pak1; Bokoch, 2003) are known to act as signaling molecules and to downregulate protein phosphatase activity (Meng et al., 2002) , effectively potentiating some cell signaling pathways. Thus, regulation of NADPH levels in the cell by Pak1 via control of PGM, in concert with other Pak1 regulatory targets, may result in a global impact on cellular metabolic and regulatory pathways.
In this context, a recent finding that PGM is a thioredoxin-interacting protein in cyanobacteria assumes importance (Lindahl and Florencio, 2003) . In these bacteria, PGM activity is shown to be inhibited under oxidizing conditions and activated by DTT and reduced thioredoxin A. It has been shown earlier that cells respond to oxidative stress by directed oxidation and inactivation of glycolytic enzymes, leading to a metabolic reshuffling of glucose equivalents through the pentose phosphate pathway. It has been proposed that this metabolic shift could provide the necessary reducing power (NADPH 2 ) for antioxidant defense mechanism for the cells (Shanmuganathan et al., 2004) . Considering that cancer cells are subjected to chronic oxidative stress and Pak1 activates PGM activity to the same extent as do thioredoxin and DTT, Pak1 could be heavily involved in helping cancer cells cope with oxidative insults in addition to mimicking a stress response in these cells. These new data also give us a fundamental understanding of the intricate cross-talk between signaling and metabolic pathways to bring about the physiological effect in the cells in response to an extracellular signal. Pak1 regulation of PGM activity also lends additional support to the proposed role of Pak1 as a regulatory switch operative in metabolic pathways, coordinately regulating cellular redox balance (Shalom-Barak and Knaus, 2002) .
There is a developing theme in cell survival research that regulation of apoptosis and glucose metabolism are closely linked (Danial et al., 2003) . Pak1 initiates cell survival pathways in part through the phosphorylation and inactivation of the proapoptotic protein, Bad (Schurmann et al., 2000) . We have now demonstrated that Pak1 also regulates the enzymatic activation of PGM, a critical regulator of cellular glucose utilization. Also, cells that have higher expression and activity of PGM seem to have a distinct growth advantage over cells that do not express PGM (Figure 7d ). Given the widespread expression and activation of Pak1 and PGM, the new mechanistic link between cell survival and energy utilization is likely to have broad relevance to normal and pathological cellular function.
Materials and methods
Cell culture and antibodies
MCF-7 breast cancer cells and K562 leukemia cells were obtained from ATCC. The antibodies used were against Pak1 (Zymed), myc tag (MBL Laboratories), T7 tag (Novagen) and PGM (a gift from Dr Richard B Marchase). DNA dye ToPro3 and fluorescent second antibodies were from Molecular Probes. Stock chemicals were from Sigma. MCF-7 cells and K562 cells were maintained in Dulbecco's modified Eagle's medium (DMEM)-F12 (1 : 1) supplemented with 10% fetal calf serum.
In vitro transcription and translation, and GST-pulldown assay
In vitro transcription and translation of the PGM or Pak1 protein was performed using the TNT-transcription-translation system (Promega). The GST-pulldown assays were performed by incubating GST protein alone or GST-test fusion proteins immobilized on GST beads with in vitro translated 35 S-labeled protein. Bound proteins were isolated by incubating the mixture for 2 h at 41C, washing 5 Â with NP40 lysis buffer, eluting the proteins with 2 Â SDS buffer, separating them on sodium dodecyl sulfate (SDS)-PAGE and developing by autoradiography as described previously (Mazumdar et al., 2001) . The amount of proteins present in the blot was visualized using Ponceau S stain.
Yeast one-on-one protein-protein interaction studies Pak1 1-270 or 270-545 aa were amplified by polymerase chain reaction (PCR) from the full-length cDNA and subcloned into a Gal4-binding domain fusion pGBD vector (Clontech). Likewise, full-length PGM cDNA was amplified by PCR and subcloned into Gal4-activation domain fusion pGAD vector (Clontech). Protein-protein interaction was verified by one-onone transformations and selection on agar plates lacking adenine, histidine, tryptophan and leucine (AHTL), and also by b-galactosidase assay as described previously .
Immunofluorescence confocal assays
The cellular localization of T7-tagged PGM and myc-tagged Pak1 was determined using indirect immunofluorescence as described previously . Briefly, cells were grown on glass coverslips and treated as described. Cells were then fixed in phosphate-buffered 4% paraformaldehyde and incubated with specific primary antibodies followed by Alexa-546-labeled goat anti-mouse antibody (red color) and Alexa-488-labelled goat anti-rabbit antibody (green color, Molecular Probes). Cellular F-actin was localized using Alexa-633-labeled phalloidin (blue color, Molecular Probes).
Pak kinase assay
In vitro kinase assays using myelin basic protein (MBP) or GST-PGM fusion protein were performed in HEPES buffer (50 mM HEPES, 10 mM MgCl 2 , 2 mM MnCl 2 , 1 mM DTT) containing 1 mg of purified bacterially expressed GST-Pak1 enzyme, 10 mCi of g-32 P-ATP and 25 mM cold ATP. The reaction was carried out in a volume of 30 ml for 30 min at 301C, and then stopped by addition of 10 ml of 4 Â SDS buffer. Reaction products were then analysed by SDS-PAGE gel and autoradiography.
Determination of the stoichiometry of the in vitro phosphorylation of PGM The stoichiometry of phosphorylation of PGM was essentially performed as described previously, with minor modifications (Zhai and Comai, 1999) . In brief, varying concentrations of PGM (1, 4, 7 and 10 mg) were subjected to in vitro phosphorylation in the presence of GST-Pak1 enzyme as described above. After 30 min of incubation, the reaction mixture was resolved by SDS-polyacrylamide gel electrophoresis (PAGE), and the protein was transferred onto a nitrocellulose membrane. The proteins were visualized by Ponceau S staining. The number of moles of PGM used was obtained from the estimated amount of PGM and its known molecular weight. The band corresponding to the PGM protein was cut and the amount t of incorporated phosphate was quantitated with a scintillation counter. According to the quantitation data, the number of moles of phosphate being transferred to PGM was obtained. The stoichiometry of PGM phosphorylation was calculated as mole(s) of phosphate transferred per mole of PGM.
Plasmid construction and mutagenesis
GST and T7 tagged PGM constructs were generated by subcloning the PGM cDNA (MGC-1682, ATCC) into the EcoR1 and XhoI sites of pGEX 5X1 (Amersham) and pcDNA3.1 (Invitrogen) vectors using primers 1 and 2 (please see Table 1 for the primer sequences). Pak1 deletion constructs have been previously described . PGM deletion constructs were generated using the PCR followed by into the EcoR1 and Xho1 sites of pGEX 5X1 by using the following primer pairs (Table 1) : (a) deletion no. 2 with primers 2 and 3; (b) deletion no. 3 with primers 2 and 4; (c) deletion no. 4 with primers 2 and 5; (d) deletion no. 5 with primers 1 and 6; (e) deletion no. 6 with primers 1 and 7; and (f) deletion no. 7 with primers 1 and 8. Mutations on PGM fulllength expression vectors were generated by site-directed mutagenesis using a Quick Change Mutagenesis Kit from Stratagene and GST-PGM as a backbone with the following primers (Table 1) : (a) PGMS459A_F and PGMS459A_R for conversion of serine 459 to alanine; (b) PGMT466A_F and PGMT466A_R for conversion of Thr 466 to alanine; and (c) PGMS504A_F and PGMS504A_R for conversion of serine 504 to alanine.
Transient transfection and electroporation
Transient transfection with the appropriate plasmids was performed using Fugene-6 (Roche Biochemical, NJ, USA) as per the manufacturer's instructions. In order to create K562-PGM stable clones, electroporation of the T7-tagged PGM expression vector into K562 cells was performed as previously described .
PGM activity assay
Bacterially expressed GST-PGM, GST-PGMT466A and GST proteins were bead purified, eluted in 20 mM glutathione, dialysed in 0.2 M Tris-HCl, pH 7.3, then concentrated to 3 mg/ ml. In all, 30 mg of protein with and without preincubation in a Pak1 or kinase-dead Pak1-K299R kinase reaction was used to measure the ability of PGM to convert G-1-P to G-6-P. Absorbance at 340 nm as a measure of NADH produced by G-6-P dehydrogenase was used as a final quantitative end point (Takahashi et al., 2001) . Reaction conditions were as follows: 24 mM G-1-P, 5 mM NAD þ , 1 U G-6-P dehydrogenase, 10 mM EDTA, 5 mM MgCl 2 and 50 mM Tris-HCl, pH 7.4. Control reactions of GST-PGM lacking the substrate G-1-P and purified GST protein alone were run in parallel with experimental reactions. PGM activity from cell lysates was measured in a similar fashion, with 100 mg of protein used in a 300 ml reaction. To obtain kinetic parameters, experimental data were fitted to theoretical equations using Excel software. Average velocity versus time was plotted and a linear regression line fit was carried out. Average velocity of the reaction was calculated based on the equation obtained from the line fit. All values are reported as the average of three replicate experiments.
Cell proliferation assay
K-562 cells and PGM clone-3 were plated in a six-well plate (2 Â 10 5 cells/well) and counted using a Coulter Counter after 4 
Reproducibility and quantitation
Results are representative of at least three replicate experiments. Bar charts are presented as the mean7s.e.m. Semiquantitation of Western blotting was performed by using software from SigmaGel.
